Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MRNA vs ALNY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ALNY Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

ALNY Overall Winner 6-Pillar Tally: MRNA 3 – 3 ALNY Matrix Metrics: MRNA 4 – 6 ALNY

As of Nov 20, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas ALNY carries 48.8/100 (HOLD) at $143.82 (14.5x Forward P/E, 19.5% operating margin).

  • Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile ALNY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs ALNY
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89
ALNY NASDAQ Head-to-Head Winner
Alnylam Pharmaceuticals, Inc.
Pharmaceutical Preparations
$143.82
-2.71% 1D
Market Cap $19.8B
TTM Revenue $5.01B
Forward P/E 14.5x
Beta / 30D Vol 0.54β · 94% Vol
Unified Composite Score
48.8 / 100 HOLD
Tech 45.0 Fund 59.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.7%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $168.22 · SMA50: $208.79

6-Pillar Scorecard Institutional Category Breakdown (MRNA 3 – 3 ALNY)

Columns: Metric · MRNA · ALNY
1. Valuation Multiples ALNY
Forward P/E 23.0x 14.5x
Trailing P/E 23.0x 7.5x
PEG Ratio N/M 0.20x
EV / Revenue 33.1x 3.9x
2. Growth & Scale MRNA
Revenue Growth (YoY) +29.2% +16.7%
Earnings Growth (YoY) -85.1% +633.5%
TTM Revenue (USD) $2.52B $5.01B
Market Cap $80.7B $19.8B
3. Profitability & Quality ALNY
Gross Margin -42.0% 77.3%
Operating Margin -80.8% 19.5%
Net Profit Margin -110.5% 52.8%
Return on Equity (ROE) -34.5% 138.1%
4. Balance Sheet & Cash Flow ALNY
Cash Generation (TTM) -$2.04B $752M
Cash Flow Margin -81.0% 15.0%
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $492M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRNA
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 89.6% (52nd %ile) 61.4% (23rd %ile)
Put/Call OI Skew 1.05x (Balanced) 1.27x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) 57.8% of Rev ($2.90B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (4) vs ALNY (6)
Institutional Metric MRNA ALNY Criterion Row Edge
Market Capitalization
Scale
$80.7B $19.8B Larger Scale MRNA
Trailing P/E Ratio
Valuation
23.0x 7.5x Lower Multiple ALNY
Forward P/E Ratio
Valuation
23.0x 14.5x Lower Multiple ALNY
Revenue Growth (YoY)
Growth
+29.2% +16.7% Higher Growth MRNA
Operating Margin (TTM)
Profitability
-80.8% 19.5% Higher Margin ALNY
Net Profit Margin
Profitability
-110.5% 52.8% Higher Margin ALNY
Return on Equity (ROE)
Capital Efficiency
-34.5% 138.1% Higher ROE ALNY
52-Week Range Position
Momentum
67% ($22–$281) 0% ($143–$477) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
2.23β · 78% Vol 0.54β · 94% Vol Lower Realized Risk MRNA
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 48.8 / 100 (HOLD) Higher Composite ALNY
Trailing 12M Revenue (USD)
Operating Scale
$2.52B $5.01B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% 77.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 33.1x EV/Rev 0.20x PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) $752M ($492M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRNA +32.95 pp
MRNA: -3.77% · ALNY: -36.72%
3M Horizon MRNA +79.46 pp
MRNA: +40.4% · ALNY: -39.06%
6M Horizon MRNA +367.61 pp
MRNA: +315.96% · ALNY: -51.65%
1Y Horizon MRNA +775.24 pp
MRNA: +706.45% · ALNY: -68.79%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MRNA Revenue ALNY Revenue MRNA Op. Margin ALNY Op. Margin Margin Leader
FY2018 $140M $70M -306.0% -1087.6% MRNA
FY2019 $60M $220M -906.8% -427.5% ALNY
FY2020 $800M $490M -95.0% -168.1% MRNA
FY2021 $18.5B $840M 72.0% -83.9% MRNA
FY2022 $19.3B $1.04B 48.9% -75.7% MRNA
FY2023 $6.85B $1.83B -61.9% -15.4% ALNY
FY2024 $3.24B $2.25B -121.9% -7.9% ALNY
FY2025 $1.94B $3.71B -158.1% 13.5% ALNY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ALNY BREAKDOWN
56d in phase · OBV DISTRIBUTION
Current IV 61.4%
IV Percentile 23rd %ile
Put/Call OI Skew 1.27x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ALNY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA vs. ALNY: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of MRNA ($21,527) vs. ALNY ($15,973) against risk-defined 5-day vertical and put-wall option structures.

MRNA Spot $215.27 · IV 83.7%
MRNA Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
ALNY Spot $159.73 · IV 50.9%
ALNY Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $165 / $180 Bull Call Spread

Buy 1x $165C · Sell 1x $180C · 32d

Net Entry $395 Debit
T+5d @ +5% Move +$161 (+41%)
Max Risk / Buffer $395 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $145 / $135 Bull Put Spread

Sell 1x $145P · Buy 1x $135P · 32d

Net Entry $165 Credit
Max Credit / Yield +$165 (+19.8% RoM)
Max Risk / Buffer -10.3% Cushion ($835 Mgn)
5d Edge & Liquidity 79% PoP · Liq B
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
ALNY Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $19.8B market capitalization and 19.5% operating margin.
OpEx & R&D Reinvestment 57.8% of Rev ($2.90B)
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs ALNY Key Questions & Quantitative Answers

As of Nov 20, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas ALNY carries 48.8/100 (HOLD) at $143.82 (14.5x Forward P/E, 19.5% operating margin). Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile ALNY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with ALNY at +16.7% YoY revenue growth and +633.5% YoY earnings growth on $5.01B TTM revenue (77.3% gross margin, 19.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRNA cumulative revenue shifted +1285.7% while ALNY shifted +5200.0%. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 57.8% of Rev ($2.90B) (0 disclosures) for ALNY.

ALNY screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas ALNY trades at 14.5x Forward P/E, 7.5x Trailing P/E, 0.20x PEG, and 3.9x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus ALNY (138.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, ALNY carries 61.4% implied volatility (23rd %ile, Compressed (<25th %ile)), a 1.27x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.54β · 94% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.